rasburicase 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
enzymes	4994	134774-45-1

Description:

Molecule	Description
Synonyms: rasburicase fasturtec elitek	a recombinant form of enzyme that degrades uric acid to allantoin just downstream of xanthine oxidase; used to treat hyperuricaemia Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

rasburicase
fasturtec
elitek

a recombinant form of enzyme that degrades uric acid to allantoin just downstream of xanthine oxidase; used to treat hyperuricaemia

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
14	mg	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Feb. 23, 2001	EMA
July 12, 2002	FDA	SANOFI SYNTHELABO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Tumour lysis syndrome	354.20	32.53	77	1992	7846	56282152
Febrile neutropenia	79.65	32.53	49	2020	105496	56184502
Hyperuricaemia	73.79	32.53	20	2049	5053	56284945
Hypofibrinogenaemia	73.34	32.53	15	2054	1122	56288876
Methaemoglobinaemia	69.02	32.53	16	2053	2146	56287852
Cytokine release syndrome	54.85	32.53	19	2050	10856	56279142
Hyperkalaemia	52.56	32.53	29	2040	50836	56239162
Blood phosphorus increased	45.35	32.53	12	2057	2764	56287234
Neutropenia	45.21	32.53	41	2028	158126	56131872
Subdural hygroma	39.44	32.53	7	2062	244	56289754
Renal failure	38.31	32.53	32	2037	110468	56179530
Cardiovascular insufficiency	37.73	32.53	9	2060	1363	56288635
Febrile bone marrow aplasia	35.14	32.53	12	2057	6560	56283438
Transverse sinus thrombosis	34.29	32.53	7	2062	518	56289480
Cerebral haematoma	34.20	32.53	10	2059	3313	56286685
Respiratory failure	33.91	32.53	28	2041	95034	56194964

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Tumour lysis syndrome	572.04	24.51	165	3866	15220	31678093
Methaemoglobinaemia	239.12	24.51	59	3972	2947	31690366
Cytokine release syndrome	113.70	24.51	51	3980	16591	31676722
Febrile neutropenia	89.91	24.51	93	3938	121756	31571557
Haemolytic anaemia	79.80	24.51	34	3997	9762	31683551
Glucose-6-phosphate dehydrogenase deficiency	60.20	24.51	11	4020	123	31693190
Immune effector cell-associated neurotoxicity syndrome	55.16	24.51	18	4013	2461	31690852
Haemolysis	52.07	24.51	23	4008	7193	31686120
Acute kidney injury	50.45	24.51	110	3921	279604	31413709
Hyperphosphataemia	47.37	24.51	16	4015	2433	31690880
Thymus hypoplasia	43.86	24.51	9	4022	191	31693122
Lymphoid tissue hypoplasia	43.86	24.51	9	4022	191	31693122
Neutropenia	38.44	24.51	66	3965	140298	31553015
Hyperuricaemia	36.01	24.51	18	4013	7420	31685893
Disseminated aspergillosis	35.19	24.51	9	4022	517	31692796
Hyperkalaemia	31.78	24.51	40	3991	64311	31629002
Sepsis	31.02	24.51	63	3968	151866	31541447
Lymphopenia	29.78	24.51	20	4011	14309	31679004
SARS-CoV-2 sepsis	29.39	24.51	6	4025	124	31693189
Myocardial calcification	29.22	24.51	5	4026	37	31693276
Hypocalcaemia	28.32	24.51	23	4008	21955	31671358
Chronic lymphocytic leukaemia	27.35	24.51	13	4018	4803	31688510
Febrile bone marrow aplasia	26.68	24.51	15	4016	7831	31685482
Toxic epidermal necrolysis	26.36	24.51	21	4010	19503	31673810
Haemophagocytic lymphohistiocytosis	25.96	24.51	17	4014	11661	31681652
Hyperbilirubinaemia	25.79	24.51	19	4012	15731	31677582

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Tumour lysis syndrome	889.35	25.71	229	5685	21131	70901399
Methaemoglobinaemia	282.18	25.71	68	5846	4718	70917812
Cytokine release syndrome	167.68	25.71	68	5846	26399	70896131
Febrile neutropenia	154.37	25.71	131	5783	204187	70718343
Haemolytic anaemia	109.25	25.71	44	5870	16750	70905780
Hyperuricaemia	86.34	25.71	33	5881	10933	70911597
Hyperkalaemia	75.50	25.71	66	5848	106525	70816005
Acute kidney injury	74.78	25.71	138	5776	474486	70448044
Neutropenia	74.40	25.71	99	5815	257057	70665473
Lymphoid tissue hypoplasia	70.72	25.71	15	5899	581	70921949
Thymus hypoplasia	69.68	25.71	15	5899	624	70921906
Hyperphosphataemia	69.09	25.71	22	5892	4254	70918276
Disseminated aspergillosis	65.86	25.71	15	5899	810	70921720
Immune effector cell-associated neurotoxicity syndrome	62.35	25.71	20	5894	3958	70918572
Glucose-6-phosphate dehydrogenase deficiency	60.10	25.71	12	5902	343	70922187
Blood phosphorus increased	59.19	25.71	22	5892	6748	70915782
Haemolysis	57.42	25.71	25	5889	11526	70911004
Sepsis	50.05	25.71	80	5834	244465	70678065
Lymphopenia	49.64	25.71	30	5884	27329	70895201
Febrile bone marrow aplasia	43.97	25.71	21	5893	11970	70910560
Respiratory failure	41.27	25.71	60	5854	168675	70753855
Chronic lymphocytic leukaemia	40.50	25.71	16	5898	5782	70916748
Hypocalcaemia	36.26	25.71	30	5884	44829	70877701
Cardiovascular insufficiency	35.72	25.71	12	5902	2741	70919789
Thrombocytopenia	34.34	25.71	67	5847	239043	70683487
Blood lactate dehydrogenase increased	33.74	25.71	26	5888	35101	70887429
SARS-CoV-2 sepsis	31.78	25.71	6	5908	127	70922403
Hypofibrinogenaemia	31.58	25.71	10	5904	1897	70920633
Myocardial calcification	30.56	25.71	5	5909	44	70922486
Blood uric acid increased	30.49	25.71	15	5899	9114	70913416
Cytomegalovirus viraemia	29.77	25.71	16	5898	11669	70910861
Renal failure	29.62	25.71	55	5859	189015	70733515
Hypertriglyceridaemia	29.61	25.71	16	5898	11795	70910735
Subdural hygroma	29.37	25.71	7	5907	461	70922069
Multiple organ dysfunction syndrome	28.58	25.71	40	5874	108475	70814055
Disseminated intravascular coagulation	28.26	25.71	23	5891	33575	70888955
Pancytopenia	27.58	25.71	47	5867	151060	70771470
Pseudomonal sepsis	27.57	25.71	12	5902	5525	70917005
Transverse sinus thrombosis	27.39	25.71	7	5907	615	70921915
Cerebral haematoma	27.29	25.71	13	5901	7365	70915165
Hypoxia	26.99	25.71	36	5878	93308	70829222

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	V03AF07	VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Detoxifying agents for antineoplastic treatment
FDA CS	M0022307	Urate Oxidase
MeSH PA	D018501	Antirheumatic Agents
MeSH PA	D006074	Gout Suppressants
FDA EPC	N0000175670	Uric Acid-specific Enzyme

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hyperuricemia	indication	35885006	DOID:1920

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
08GY9K1EUO	UNII
D05704	KEGG_DRUG
4021376	VUID
N0000148794	NUI
C0937932	UMLSCUI
CHEMBL1201594	ChEMBL_ID
DB00049	DRUGBANK_ID
7851	INN_ID
C469709	MESH_SUPPLEMENTAL_RECORD_UI
7467	IUPHAR_LIGAND_ID
283821	RXNORM
16841	MMSL
44374	MMSL
53180	MMSL
d04805	MMSL
009162	NDDF
134670005	SNOMEDCT_US
395858003	SNOMEDCT_US
415249009	SNOMEDCT_US
4021376	VANDF

Pharmaceutical products:

None